INTRODUCTION

Diabetes mellitus is a group of metabolic disorder is characterized by hyperglycemia and disturbances of carbohydrate, lipid, and protein metabolism. Long-term hyperglycemia during diabetes causes glycation of body proteins that lead to secondary complications affecting kidney, eye, nerve, and arteries. It is considered as one of the five leading causes of death in the world [1]. Altogether diabetes has shadowed the spread of modern lifestyle, and it can be associated to surge overweight and sedentary inhabitants [2]. The global problem of diabetes mellitus stances massive social expenses and has chief implications for all healthcare structures. Diabetic dyslipidemia results in accumulation of excess free fatty acids (FFA), which are converted to triglycerides (TGs) in the liver. The consequence of fat accumulation is increased small dense low-density lipoprotein cholesterol (LDLc) and TGs levels and decreased high-density lipoprotein cholesterol (HDLc), which contributes to cardiovascular risk in diabetes. It is now well-known that the hyperlipidemia signifies a major risk factor for the premature development of diabetes and its complications.

Experimental models using animal provide clear clues for the understanding of the molecular and pathological state of diabetes mellitus and are valuable for the screening of drugs for the prevention and management of diabetes. The pathophysiology of diabetes involves a very complex cascade of several interrelated mechanisms. Alloxan is a universally used chemical to produce experimental diabetic animals in the labs for its ability to damage insulin-producing beta cells. It is generally accepted that free radicals generated by alloxan cause beta cell injury that is key to its part as a diabetogenic agent. As it has been widely accepted that alloxan selectively destroys the insulin-producing beta cells found in the pancreas; hence, it is used to induce diabetes in laboratory animals.

There is increasing demand by patients to use natural products with anti-diabetic activity due to side effects associated with the use of oral hypoglycemic agents. Many of the currently available oral hypoglycemic drugs possess a number of serious toxic effects [3]. Meanwhile, the management of diabetes mellitus without adverse effects is still a major challenge. Dietary involvement, mostly the practice of traditional medicine derived from natural sources, is a major strength in the management of diabetes [4].

Traditionally, a number of plants have been used in various herbal preparations in the management of diabetes and only a few of them have been proven scientifically. Plant drugs are considered to be less toxic and free from side effects than synthetic ones [5]. *Senna surattensis* (Caesalpiniaceae) is commonly known as Glauces cassis and distributed throughout India. It is commonly used in folk medicine as antihyperglycemic for the management of diabetes mellitus [6,7]. The plant is also known for its use in gonorhoea blemorrhoea and jaundice. Bark, aerial parts and leaves are useful in for the management of diabetes and gonorhoea [8]. The plant found to contain anthraquinone, flavonol glycosides, chrysophanol, physcion, kaempferide, and queretin [9]. The extracts of *S. surattensis* have been shown to have antimicrobial, antihyperlipidemic, antioxidant, and hepatoprotective activities [10-13]. We have also previously demonstrated the hypoglycemic effect of ethanolic extracts of *S. surattensis* (EESS) using *in vitro* models of diabetes mellitus [14]. Literature surveys have yielded scanty information on the pharmacological properties of *S. surattensis* for diabetes management. However, no systematic study was carried out on the leaf extracts of *S. surattensis* for its *in vivo* anti-diabetic activity using an animal model. Hence, the present study first time aimed to investigate the anti-diabetic activity of leaf extracts of *S. surattensis* using alloxan treated diabetic rats to ascertain the scientific basis for the use in the treatment of diabetes mellitus. Here, the antihyperglycemic
activity of EESS is evaluated in detail with scientific approach including its effects on biochemical parameters.

METHODS

Plant materials
Fresh leaves of *S. surattensis* were collected from Tiruchirappalli (Tamil Nadu, India) in December 2006 and authenticated by the Botanical Survey of India (Coimbatore, Tamil Nadu, India; Ref. No.: BSI/SC/5/23/06-07/Tech-1638). An authentic voucher specimen was deposited in the Herbarium Division of Pharmacognosy, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.

Preparation of plant extract
The collected leaves of *S. surattensis* were air dried at room temperature without exposure to sunlight, coarsely powdered. 30 g of the powdered leaf was packed in Soxhlet apparatus and extracted with ethanol (95%). The solvent was then evaporated under reduced pressure in a rotary evaporator (Superfit, India) at 40°C to obtain a dry extract (yield 24.25% w/w) that was stored at -20°C in a refrigerator until further use. The extracts were subjected to a qualitative test for the identification of various phytochemical constituents as per the standard procedures [15]. The dose of each extract was calculated according to body weight (bw) before administration to the diabetic rats.

Animals and ethical approval
Male Wistar albino rats weighing about 250–300 g bw were used in the present study (M/S Ghosh Enterprises, Kolkata, India). The animals were collected from a breeding colony they were housed in polypropylene cages and fed with commercial diet from Hindustan Lever Ltd. (Bangalore, India) and had free access to water ad libitum during the experiment. The animals were acclimatized to the laboratory condition (temperature 21±2°C with a light period (7.00 a.m to 7 p.m. and relative humidity 55–70%) for 2 weeks before the start of the experiment. The experiments were performed compiled with the rulings of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) New Delhi, India (Registration No: 0367/01/C/CPCSEA), and the study was permitted by the Institutional Animal Ethical Committee (IAEC) of the Jadavpur University, Kolkata.

Induction of experimental diabetes mellitus
Diabetes was induced by a single intraperitoneal injection of alloxan monohydrate (150 mg/kg bw) in a freshly prepared sterile normal saline solution [16]. Diabetes was confirmed by measuring fasting blood glucose (FBG) level 72 h after injection only rats with glucose level >300 mg/dl as well as with polydipsia, polyuria, and polyphagia was selected for the experiment.

Experimental design
In this study, a total of 30 rats (24 diabetic surviving rats and 6 normal rats) were used. The rats were divided into five groups (n=6). The Group 1 (non-diabetic control) and Group 2 (diabetic control) rats received 2% Tween 80 (2 ml/kg bw), while Group 3 and 4 diabetic rats treated with EESS (200 mg/kg and 400 mg/kg) and glibenclamide (5 mg/kg) once a day using intragastric tube for 21 days. Group 5 diabetic rats were treated with EESS (200 and 400 mg/kg) and glibenclamide (5 mg/kg), the serum transaminases level was brought back to almost near normal levels (p<0.01).

Estimation of biochemical parameters
FBG was measured by ACCU-Chek Touch Glucometer (Accu-Chek, Roche Diagnostic, USA). Changes in bw were estimated at the end of experiments. Serum biomarkers such as serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), FFA, PLs, HbA1C, HDLc, LDLc, TGs, TC, total protein, and albumin were measured by spectrophotometrically (Spekol 1200, Japan) using Span diagnostic Kits (Mumbai, India).

Statistical analysis
Data were statistically evaluated using one-way analysis of variance, followed by Dunnett’s t-test using GraphPad InStat Statistical software (San Diego, CA, USA). The values were considered significant when p<0.01 and p<0.05.

RESULTS

Effect on FBG and bw
Changes in FBG and bw in diabetic control and EESS treatment were presented in Figs. 1 and 2. In this study, alloxan-induced diabetic rats showed significant (p<0.01) reduction in bw. FBG levels of the diabetic control rats were higher than those of normal rats. Administration of EESS (200 and 400 mg/kg) and glibenclamide (5 mg/kg) significantly (p<0.01) increased the bw within 21 days. After administration of EESS a significant (p<0.01) dose-dependent decrease in FBG levels was observed compared with diabetic control group.

Effect on serum liver profile
Fig. 3 showed the liver biomarker such as SGOT, SGPT, and ALP in the serum of control and experimental groups. Serum transaminases SGOT, SGPT, and ALP levels were significantly increased in the diabetic control rats. After treatment with EESS (200 mg/kg and 400 mg/kg) and glibenclamide (5 mg/kg), the serum transaminases level was brought back to almost near normal levels (p<0.01).

Effect on serum lipid profile
The level of FFAs, PLs, TC, TGs, HDLc, and LDLc in the serum of EESS treated and control diabetic rats are presented in Fig. 4. Significant
reductions in serum HDLc were observed in alloxan-induced diabetic rats when compared to control rats (Group 1). On administration of EESS (200 mg/kg and 400 mg/kg) for 21 days to the diabetic rats, serum HDLc levels were found to be restored in normal. Furthermore, the fatty acids, phospholipids (PL), total cholesterol (TC), TGs, and LDLc levels were elevated significantly in alloxan-induced control diabetic rats compared to control rats. Both the doses of EESS and glibenclamide treatment significantly (p<0.01) reduced above parameters compared to diabetic control rats.

**Effect on total protein, albumin, and HbA1C**

Figs. 5 and 6 showed the effect of EESS and glibenclamide on total protein and albumin in control and alloxan diabetic rats. Significant reductions in serum protein and albumin were observed in alloxan-induced diabetic rats (Group 2) when compared to control rats (Group 1). On administration of EESS to the diabetic rats, serum protein albumin and protein levels were found to be restored in normal. Furthermore, the HbA1C level was elevated significantly in alloxan-induced diabetic rats compared to control rats. Both the doses of EESS and glibenclamide treatment significantly reduced HbA1C compared to diabetic control rats.

**DISCUSSION**

Diabetes mellitus is perhaps the fastest-developing metabolic disorder in worldwide, which raises the need for more challenging and appropriate treatments. Traditional medicinal plant approaches have been used for many centuries in the treatment of diabetes. In India, *S. surattensis* leaves are widely used in folk medicine by diabetic patients to attenuate hyperglycemia caused by diabetes mellitus. This plant has been traditionally used in many countries as food products and for medicinal uses. *S. surattensis* flowers and leaves have been studied extensively, and the therapeutic properties such as antioxidant, hepatoprotective, and antimicrobial and have been reported [17,18]. The phytochemical analysis has shown the presence of potent phytochemicals such as flavonoids, terpenoids, glycosides, steroids, saponin, and phenols. It has long been used to treat diabetes mellitus and related hyperlipidemia. However, its pharmacological bases are not well understood in animal models of diabetes mellitus. The results of this study indicated that EESS not only possessed significant hypoglycemic effect but also had remarkable hypolipidemic effect in alloxan-induced diabetic rats.

In this study, the administration of alloxan, as expected, caused by significant hyperglycemia and elevated serum lipid levels. Alloxan, a cytotoxic agent, causes a condition of insulin-dependent diabetes through its ability to induce reactive oxygen species formation, leading to selective necrosis of the pancreatic beta cells [19,20]. Thus, alloxan injection results in pancreas β-cell death and histological changes then leads to the decrease of serum insulin level and elevation of glucose level. Before EESS treatment of alloxan-induced diabetic rats, the substantial rise in FBG was associated with increases in TC and TGs and decrease of HDLc. After EESS treatments, FBG, TC, and TGs of all tested rats were significantly decreased, and at the same time, HDLc was increased. Hyperlipidemia is one of the major cardiovascular risk
factors. Diabetes is associated with profound changes in serum lipid levels which increase the risk of metabolic syndrome [21]. Prolonged oral administration of EESS for 3 weeks ensued in major progress of serum lipid profile in alloxan-treated diabetic rats. It is well known that hyperglycemia is the main factor of plasma VLDLc and TGs [22], so the strong hypolipidemic effect of EESS could also be facilitated by the improvement of hyperglycemia.

HbA1C is considered as an important diagnostic marker and helps to know about the degree of protein glycation, long-term blood sugar level and correlation of diabetes-associated complications. HbA1C is abnormally high in diabetes, with chronic hyperglycemia and reflect their metabolic control [23,24]. HbA1C was found to be increased in patients with diabetes mellitus for approximately 16%, and the amount of increase was found directly proportional to the FBG level. In this study, alloxan-induced diabetic rats showed a significant increase (p<0.01) HbA1C level compared with normal rats. The ethanol extract of S. surattensis leaf treated rats showed a significant decrease (p<0.01) in the content of HbA1C that could be due to an improvement in glycemic status.

The decrease in bw in diabetic as clearly shows a loss or degradation of structural proteins due to diabetes. The ability of the EESS to protect from maximum bw loss seems to be due to its ability to reduce hyperglycemia. The decrease in TP and albumin may be due to microproteinuria and albuminuria, which are important clinical markers of diabetic nephropathy, and/or may be due to increased protein catabolism [25]. The results of the present study confirmed significant raise in TP and albumin to be similar to their normal levels after the treatment of the diabetic rats with EESS. Furthermore, elevated serum SGOT, SGPT, and ALP levels were described in diabetes mellitus, and it may be due to liver dysfunction [26]. In this study, an elevated level of SGOT, SGPT, and ALP was observed in alloxan-induced diabetic rats which may have occurred by leakage of enzymes from the liver cytosol into the bloodstream; it represents the toxicity of alloxan on the liver. Diabetic rats treated with EESS significantly decreased SGOT, SGPT, and ALP levels, which signify the protective effect of EESS in alloxan-treated diabetic rats. Moreover, it was reported earlier that the extract of S. surattensis did not show any signs of toxicity based on acute oral toxicity studies [27].

CONCLUSION
Diabetes mellitus has been a serious metabolic disorder all over the world. Medicinal plants play a key role in the treatment of diabetes due to their active constituents. Current results have confirmed that polyphenolic compounds and flavonoids are major bioactive components of the hypoglycemic effect of EESS. However, their detailed mechanisms of action need further investigation. In summary, the present study has shown that S. surattensis extracts validate clears hypoglycemic and hypolipidemic effects in alloxan-induced diabetic rats. This study is supportive for understanding mechanism of action of EESS, and also exposes the potential of S. surattensis for use as a natural oral hypoglycemic agent with hypolipidemic effects. However, longer duration of chronic studies is necessary to elucidate the exact mechanism of action so as to develop it as a potent anti-diabetic drug.

ACKNOWLEDGMENTS
The authors are grateful to All India Council for Technical Education (New Delhi, India) for providing financial support through its Quality Improvement Scheme (QIP).

REFERENCES